Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency

Franco, Celina; Johannsson, Gudmundur; Bengtsson, Bengt‐Åke; Svensson, Johan

doi:10.1210/jc.2006-0887

Cited by 34 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…lipid profiles (11,15,16,21,23). In general, rhGH treatment decreased total and low density lipoprotein (LDL) cholesterol levels by 4-8% (15,16,23) and by 11-16%, respectively, whereas rhGH increased high density lipoprotein (HDL) only by 17% in one other study (16).…”

Section: Effects Of Rhgh On Cardiovascular and Metabolic Parametersmentioning

confidence: 93%

“…Two studies did not specify the age of the patient, but only indicate that all patients are O60 years (10,11). One study assessed patients between the age 60 and 70 years (22), and in three studies, the age ranged between 60 and 75 years (12,21,23). Five studies included patients O75 years and only two of these studies included patients with age O80 years (14-17, 24).…”

Section: Study Designsmentioning

confidence: 99%

“…Different tests, however, were used, including insulin tolerance test (ITT), combined GHRH plus arginine (GHRHCarginine) test, glucagon stimulation test or stimulation with arginine alone (Table 1). The ITT was used in the total population or in the majority of patients in seven studies (11,12,15,17,(21)(22)(23). The study by Koltowska et al (10) did not mention which tests were used to diagnose GHD.…”

Section: Endocrine Evaluationmentioning

confidence: 99%

“…Seven of the 11 studies used age-adjusted IGF1 levels measured in a control population to titrate rhGH dose (11,12,14,16,(21)(22)(23) All studies titrated the rhGH dose with the aim of normalizing IGF1 S.D. scores, i.e.…”

Section: Igf1 Levels and Sd Scoresmentioning

confidence: 99%

“…Feldt-Rasmussen et al (11) and Monson et al (15) both took the clinical response into account when titrating rhGH dose, referring to a study by Drake et al (26), in which waist/hip (W/H) measurements and improvement of QoL measured by AGHDA were taken into account for the titration of the dose. The remaining two studies (12,23) both state that, when adjusting the rhGH dose, the aim is to 'normalizing IGF1 and BC. ', both referring to a study by Johannssen et al (7), in which individualized doses of rhGH are compared with doses based on body weight.…”

Section: Igf1 Levels and Sd Scoresmentioning

confidence: 99%

See 4 more Smart Citations

GH replacement therapy in elderly GH-deficient patients: a systematic review

Kokshoorn

Biermasz

Roelfsema

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Context: Recombinant human GH (rhGH) is prescribed for the treatment of adults with GH deficiency (GHD). However, conflicting data are available on the efficacy of rhGH treatment in elderly GHD patients. Objective: To assess the efficacy of rhGH treatment in elderly GHD subjects. Methods: We searched the available literature in PubMed, Cochrane Library, Web of Science and EMBASE. Study selection: Studies on GHD patients, aged O60 years, treated with rhGH were eligible for inclusion. Data extraction was performed by two reviewers independently. Results: We found 11 eligible studies with a total of 534 patients. Only two studies had prospective, randomized, placebo-controlled study designs of rhGH treatment with a duration of 6 (nZ15) and 12 months (nZ62), respectively. Treatment with rhGH decreased total and low density lipoprotein (LDL) cholesterol levels by 4-8 and 11-16%, respectively, but did not alter high density lipoprotein or triglyceride levels. RhGH did not affect body mass index, but decreased waist circumference (by w3 cm) and waist/hip ratio. RhGh did not consistently affect blood pressure or bone mineral density. RhGH increased lean body mass by 2-5% and decreased total fat mass by 7-10% in four studies, but did not affect body composition in two other studies. RhGH consistently improved quality of life (QoL) parameters reflected in AGHDA-scores. There were no explicit data on elderly GHD patients aged O80 years. Conclusion: RhGH replacement in elderly subjects with GHD decreases LDL cholesterol levels and improves QoL, but the effects on other parameters are not unequivocal. There were no data on the efficacy and safety of rhGH treatment in octogenarians with GHD.

show abstract

Section: Effects Of Rhgh On Cardiovascular and Metabolic Parametersmentioning

confidence: 93%

Section: Study Designsmentioning

confidence: 99%

Section: Endocrine Evaluationmentioning

confidence: 99%

Section: Igf1 Levels and Sd Scoresmentioning

confidence: 99%

Section: Igf1 Levels and Sd Scoresmentioning

confidence: 99%

See 3 more Smart Citations

GH replacement therapy in elderly GH-deficient patients: a systematic review

Kokshoorn

Biermasz

Roelfsema

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

Risks and Benefits of Growth Hormone Replacement in the Elderly

Labadzhyan

Melmed²

2022

Pituitary Disorders Throughout the Life Cycle

View full text Add to dashboard Cite

Hypopituitarism in the elderly: two case-reports with heterogeneous presentation

et al. 2009

View full text Add to dashboard Cite

Hypopituitarism (HYPO) is an under-investigated disease in older patients. Symptoms, which may be life-threatening, are aspecific and often attributed to aging and/or related morbidities. We describe here the cases of two elderly patients who were ultimately diagnosed as having HYPO, the clinical presentations and etiologies of which were different. In the first patient, an invasive non-secreting pituitary macroadenoma causing HYPO was detected on brain morphological evaluation for head trauma secondary to falling. Glucocorticoid replacement therapy was started. Thyroid function evaluation showed hyperthyroidism (due to a known toxic multinodular goiter), which was already on treatment with methimazole; ultimately, after withdrawal of the antithyroid drug, secondary hypothyroidism occurred. The patient underwent non-radical pituitary surgery. Cognitive function, gait impairment and falling, which had previously been attributed only to aging, improved markedly after cortisone acetate and L-thyroxine replacement therapy. The second patient was hospitalized one month after the onset of hypotension, edema and pain in the legs, and progressive psychomotor impairment, which ultimately resulted in an intermittent soporous state. She was diagnosed as having global anterior HYPO secondary to empty sella, which caused severe multifaceted clinical and biochemical abnormalities (hyponatremia, pancytopenia, rhabdomyolysis). After treatment with i.v. fluids and hydrocortisone, the patient's clinical condition and biochemical alterations improved, and normalized over time with oral cortisone acetate and Lthyroxine combination therapy. Several protean symptoms that impair the quality of life of elderly patients are usually ascribed to aging. Such symptoms should be investigated with regard to possible HYPO, treatment of which can result in significant clinical benefit.

show abstract

Baseline Characteristics and Effects of Growth Hormone Therapy over Two Years in Younger and Elderly Adults with Adult Onset GH Deficiency

Abstract: This study identifies elderly GHD adults as a GH-sensitive group in whom a low dose of GH can improve body composition and serum lipid profile without any significant impairment of glucose metabolism. GH replacement should therefore be considered in elderly GHD adults.

Cited by 34 publications

References 25 publications

GH replacement therapy in elderly GH-deficient patients: a systematic review

GH replacement therapy in elderly GH-deficient patients: a systematic review

Risks and Benefits of Growth Hormone Replacement in the Elderly

Hypopituitarism in the elderly: two case-reports with heterogeneous presentation

Contact Info

Product

Resources

About